122 related articles for article (PubMed ID: 35189247)
1. Objective assessment of adrenocortical carcinoma driver genes and their correlation with tumor pyruvate kinase M2.
Das R; Ghosh Chowdhury M; Raundal S; Jadhav J; Kumar N; Patel S; Shard A
Gene; 2022 May; 822():146354. PubMed ID: 35189247
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive analysis of CTNNB1 in adrenocortical carcinomas: Identification of novel mutations and correlation to survival.
Maharjan R; Backman S; Åkerström T; Hellman P; Björklund P
Sci Rep; 2018 Jun; 8(1):8610. PubMed ID: 29872083
[TBL] [Abstract][Full Text] [Related]
3. Integrated genomic characterization of adrenocortical carcinoma.
Assié G; Letouzé E; Fassnacht M; Jouinot A; Luscap W; Barreau O; Omeiri H; Rodriguez S; Perlemoine K; René-Corail F; Elarouci N; Sbiera S; Kroiss M; Allolio B; Waldmann J; Quinkler M; Mannelli M; Mantero F; Papathomas T; De Krijger R; Tabarin A; Kerlan V; Baudin E; Tissier F; Dousset B; Groussin L; Amar L; Clauser E; Bertagna X; Ragazzon B; Beuschlein F; Libé R; de Reyniès A; Bertherat J
Nat Genet; 2014 Jun; 46(6):607-12. PubMed ID: 24747642
[TBL] [Abstract][Full Text] [Related]
4. Tumor treating fields (TTFields) impairs aberrant glycolysis in glioblastoma as evaluated by [
Patel CB; Beinat C; Xie Y; Chang E; Gambhir SS
Neoplasia; 2021 Jan; 23(1):58-67. PubMed ID: 33221711
[TBL] [Abstract][Full Text] [Related]
5. Mass-array screening of frequent mutations in cancers reveals RB1 alterations in aggressive adrenocortical carcinomas.
Ragazzon B; Libé R; Assié G; Tissier F; Barreau O; Houdayer C; Perlemoine K; Audebourg A; Clauser E; René-Corail F; Bertagna X; Dousset B; Bertherat J; Groussin L
Eur J Endocrinol; 2014 Mar; 170(3):385-91. PubMed ID: 24347427
[TBL] [Abstract][Full Text] [Related]
6. Pyruvate Kinase M2 Modulates Esophageal Squamous Cell Carcinoma Chemotherapy Response by Regulating the Pentose Phosphate Pathway.
Fukuda S; Miyata H; Miyazaki Y; Makino T; Takahashi T; Kurokawa Y; Yamasaki M; Nakajima K; Takiguchi S; Mori M; Doki Y
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1461-8. PubMed ID: 25808097
[TBL] [Abstract][Full Text] [Related]
7. PKM2 Promotes Cell Survival and Invasion Under Metabolic Stress by Enhancing Warburg Effect in Pancreatic Ductal Adenocarcinoma.
Li C; Zhao Z; Zhou Z; Liu R
Dig Dis Sci; 2016 Mar; 61(3):767-73. PubMed ID: 26500118
[TBL] [Abstract][Full Text] [Related]
8. Notch1 pathway in adrenocortical carcinomas: correlations with clinical outcome.
Ronchi CL; Sbiera S; Altieri B; Steinhauer S; Wild V; Bekteshi M; Kroiss M; Fassnacht M; Allolio B
Endocr Relat Cancer; 2015 Aug; 22(4):531-43. PubMed ID: 25979380
[TBL] [Abstract][Full Text] [Related]
9. Suppressed "Warburg Effect" in Nasopharyngeal Carcinoma Via the Inhibition of Pyruvate Kinase Type M2-Mediated Energy Generation Pathway.
Zhao P; Zhou M; Chen R; Su R
Technol Cancer Res Treat; 2020; 19():1533033820945804. PubMed ID: 32815467
[TBL] [Abstract][Full Text] [Related]
10. PKM2 Modulation in Head and Neck Squamous Cell Carcinoma.
Boschert V; Teusch J; Müller-Richter UDA; Brands RC; Hartmann S
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054968
[TBL] [Abstract][Full Text] [Related]
11. Enhanced expression of the M2 isoform of pyruvate kinase is involved in gastric cancer development by regulating cancer-specific metabolism.
Shiroki T; Yokoyama M; Tanuma N; Maejima R; Tamai K; Yamaguchi K; Oikawa T; Noguchi T; Miura K; Fujiya T; Shima H; Sato I; Murata-Kamiya N; Hatakeyama M; Iijima K; Shimosegawa T; Satoh K
Cancer Sci; 2017 May; 108(5):931-940. PubMed ID: 28235245
[TBL] [Abstract][Full Text] [Related]
12. The Role of PKM2 in Metabolic Reprogramming: Insights into the Regulatory Roles of Non-Coding RNAs.
Puckett DL; Alquraishi M; Chowanadisai W; Bettaieb A
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33503959
[TBL] [Abstract][Full Text] [Related]
13. Pyruvate kinase type M2 contributes to the development of pancreatic ductal adenocarcinoma by regulating the production of metabolites and reactive oxygen species.
Yokoyama M; Tanuma N; Shibuya R; Shiroki T; Abue M; Yamamoto K; Miura K; Yamaguchi K; Sato I; Tamai K; Satoh K
Int J Oncol; 2018 Mar; 52(3):881-891. PubMed ID: 29393401
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Proliferation, Migration, and Invasion by Knockdown of Pyruvate Kinase-M2 (PKM2) in Ovarian Cancer SKOV3 and OVCAR3 Cells.
Miao Y; Lu M; Yan Q; Li S; Feng Y
Oncol Res; 2016 Oct; 24(6):463-475. PubMed ID: 28281967
[TBL] [Abstract][Full Text] [Related]
15. Pyruvate kinase M2 (PKM2) in cancer and cancer therapeutics.
Zhu S; Guo Y; Zhang X; Liu H; Yin M; Chen X; Peng C
Cancer Lett; 2021 Apr; 503():240-248. PubMed ID: 33246091
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation of pyruvate kinase M2 and lactate dehydrogenase A by fibroblast growth factor receptor 1 in benign and malignant thyroid tissue.
Kachel P; Trojanowicz B; Sekulla C; Prenzel H; Dralle H; Hoang-Vu C
BMC Cancer; 2015 Mar; 15():140. PubMed ID: 25880801
[TBL] [Abstract][Full Text] [Related]
17. The transcription factor TEAD4 enhances lung adenocarcinoma progression through enhancing PKM2 mediated glycolysis.
Hu Y; Mu H; Deng Z
Cell Biol Int; 2021 Oct; 45(10):2063-2073. PubMed ID: 34196069
[TBL] [Abstract][Full Text] [Related]
18. Activators of PKM2 in cancer metabolism.
Warner SL; Carpenter KJ; Bearss DJ
Future Med Chem; 2014 Jun; 6(10):1167-78. PubMed ID: 25078136
[TBL] [Abstract][Full Text] [Related]
19. Moderate DNA damage promotes metabolic flux into PPP via PKM2 Y-105 phosphorylation: a feature that favours cancer cells.
Kumar B; Bamezai RN
Mol Biol Rep; 2015 Aug; 42(8):1317-21. PubMed ID: 25840825
[TBL] [Abstract][Full Text] [Related]
20. Organ-Specific MicroRNAs (
Taniguchi K; Sugito N; Shinohara H; Kuranaga Y; Inomata Y; Komura K; Uchiyama K; Akao Y
Int J Mol Sci; 2018 Apr; 19(5):. PubMed ID: 29695138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
